QMS Medical Allied Services reports 31.65% rise in Q1 FY26 PAT to Rs. 3.15 Cr
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Subscribe To Our Newsletter & Stay Updated